Ferring Licenses Late-Stage Constipation Drug from AstraZeneca Spinout Albireo
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 7 (Table of Contents)
Published: 11 Jul-2012
DOI: 10.3833/pdr.v2012.i7.1766 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Ferring Pharmaceuticals has entered into a licensing agreement with Albireo, which was spun-out from AstraZeneca in 2008, for elobixibat, which is ready to enter Phase III development for chronic idiopathic constipation and Phase IIb development for irritable bowel syndrome with constipation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS